Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

Abiraterone

J&J drug offers hope in advanced prostate cancer

Men with advanced prostate cancer lived nearly four months longer on a new pill from Johnson & Johnson, according to keenly awaited study data that researchers said would change clinical practice.

Abiraterone, which could reach the market next year, provides a new option for men with an aggressive type of prostate cancer.

Its… J&J drug offers hope in advanced prostate cancer   



J&J’s prostate cancer drug approved in EU

Johnson & Johnson’s prostate cancer drug Zytiga has been approved in the European Union, paving the way for the launch of a new treatment for men whose disease has progressed after chemotherapy, the company said on Wednesday.

The decision was expected after European regulators endorsed the treatment in July. J&J’s Janssen unit has European… J&J’s prostate cancer drug approved in EU   



diagnostic testing1 - pca1 - uropathogenic e. coli1 - hemorrhagic inflammation1 - catheter malfunction1 - proteins rala1 - burning2 - aua1 - bone metastases3 - congenital malformations of urinary tract1 - american cancer society1 - plco study1 - renal dysplasia1 - hypoalbuminemia1 - azoospermia1 - proton therapy1 - lpn1 - abbott diagnostics1 - niddk1 - local recurrence1 - pet1 - cyclind11 - renal ultrasonography1 - biomarkers1 - diarrhea1 - esrd6 - erectile dysfunction5 - bladder regeneration1 - implantable contraception1 - rokitansky syndrome1 -